Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03852511 · ClinicalTrials.gov registry record · Phase 1
First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)
A Phase 1 study, sponsored by Akamis Bio.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT03852511 is a Phase 1 study that has completed, run by Akamis Bio. The registered enrollment target is 28 participants.
The verdict
NCT03852511, a Phase 1 study, has completed, sponsored by Akamis Bio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability and preliminary efficacy and also pharmacokinetics, immunogenicity and other pharmacodynamic effects to elucidate the mechanism of action of NG-350A, either alone or in combination with a check point inhibitor, in patients with advanced or metastatic epithelial tumours.
Interventions
- BIOLOGICAL NG-350A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2019-02-19 |
| Est. Completion | 2022-02-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03852511
The ClinicalTrials.gov registry entry for NCT03852511 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akamis Bio, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NG-350A is the first listed.
NCT03852511 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03852511 about?
NCT03852511 is a clinical study titled "First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)". This study will evaluate the safety, tolerability and preliminary efficacy and also pharmacokinetics, immunogenicity and other pharmacodynamic effects to elucidate the mechanism of action of NG-350A, either alone or in combination with a check point inhibitor, in patients with advanced or metastatic...
What is the current status of trial NCT03852511?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2019-02-19. Estimated completion is 2022-02-04.
What interventions are being tested in trial NCT03852511?
The interventions under investigation include: NG-350A (BIOLOGICAL).
Who is sponsoring clinical trial NCT03852511?
This trial is sponsored by Akamis Bio, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.